Hereditary orotic aciduria is a rare hereditary disease caused by deficiency in the enzyme uridine-5’-monophosphate synthase, which is involved in pyrimidine metabolism. This leads to accumulation of orotic acid in the urine, resulting in vomiting, fatigue, and developmental delay if untreated. Treatment of the condition involves pyrimidine supplementation using natural occurring pyrimidines or its precursors like uridine. The global hereditary orotic aciduria market comprises drugs for treatment of this rare disease.

The Hereditary Orotic Aciduria Market Growth is estimated to be valued at US$ 357.9 MN in 2024 and is expected to exhibit a CAGR of 5.2% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the hereditary orotic aciduria market are Merck & Co. Inc. and SERB Pharmaceuticals. Merck & Co. Inc. offers drug Pyrimidine-5 which is used for treatment of hereditary orotic aciduria. SERB Pharmaceuticals also offers pyrimidine supplements for managing symptoms associated with this rare disease.

The growing diagnosis rate of hereditary orotic aciduria and increasing awareness about available treatment options is driving the demand in the market. With newborn screening programs implemented in various countries, many new cases are being identified each year supporting market growth.

The major pharmaceutical companies are also expanding their hereditary orotic aciduria treatment options globally. Merck & Co. Inc. has registration of Pyrimidine-5 in key markets and is working to penetrate other regions. SERB Pharmaceuticals is also actively promoting its pyrimidine supplements in international markets. This global expansion is allowing more patients to access dedicated therapy.

Market Drivers

The increasing research funding and initiatives to develop new treatment methods for rare diseases like hereditary orotic aciduria is a key driver for this market. Government organizations as well as pharmaceutical companies are conducting clinical trials to develop gene therapy and other innovative treatment strategies. This is expected to offer more effective solutions and propel the hereditary orotic aciduria market growth over the forecast period.